Colon Cancer Clinical Trial
Official title:
Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial
A prospective Randomized Clinical Trial to investigate the Effect ofPeri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis
Colon cancer (colorectal cancer CRC) is one of the most common malignant tumor of digestive
tract, has become the global incidence of third malignant tumors, including colorectal
cancer proportion increased year by year. With the way of life of residents in our country,
the adjustment of diet and aging progress, the incidence of colorectal cancer is rising the
trend, and most patients have been found in advanced disease. Tumor metastasis is an
important factor affecting the prognosis of colon cancer, liver metastasis, especially,
including simultaneous liver metastases and delayed liver metastasis from colon cancer,
about 20% to 34% will appear at the same time of liver metastasis, about 40-50% of CRC
patients died of liver metastasis at present, multi disciplinary team treatment to surgical
treatment of the absolute dominance of the more and more attention, and benefit, but the
optimum sequence of chemotherapy and surgery, is still unclear. The preoperative
chemotherapy Potential advantages include: early treatment of micrometastasis; assessment of
tumor response to chemotherapy (with prognostic value, contribute to the development of
postoperative treatment plan); for those patients with early progression can avoid local
treatment. Preoperative treatment of the potential disadvantages include: missed the surgery
opportunity window period ", probably because in early stage of tumor progress, may also be
because chemotherapy achieved complete remission and to determine the extent of resection
surgery has become extremely difficult.2015 second edition of the NNCN guidelines that
resectable metastatic disease initial resectable patients may be liver resection, adjuvant
chemotherapy and postoperative; another alternative treatment mode is around perioperative
chemotherapy (perioperative chemotherapy and postoperative chemotherapy). Therefore, gaps in
the determination of the timing of chemotherapy is still the guide, worth exploring.
I center to carry out laparoscopic resection of colon cancer has been more than ten years,
the accumulated number of cases more than 1000 cases, with rich experience of colon cancer.
Comprehensive treatment including surgery, oncology, Radiology, pathology, Department of
radiotherapy, a number of departments, the Department of endoscopy MDT team, and won the
outstanding team of Chinese Medical Doctor Association in 2016 MDT honor.
This study used a prospective randomized method, evaluation of colon cancer with
simultaneous resectable liver metastatic lesions and peri chemotherapy surgery after
neoadjuvant chemotherapy of two therapeutic schemes for short-term and long-term effect, is
expected to summarize the prospective data to support the operation and chemotherapy
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT03457454 -
Reducing Rural Colon Cancer Disparities
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03390907 -
Hybrid APC Assisted EMR for Large Colon Polyps
|
N/A | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT04079478 -
The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
|
||
| Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
| Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05147545 -
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
|
N/A | |
| Recruiting |
NCT05026268 -
The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis
|
N/A | |
| Not yet recruiting |
NCT03277235 -
Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT02730702 -
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
|
||
| Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
| Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
| Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
| Recruiting |
NCT02526836 -
Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer
|
Phase 2/Phase 3 |